Ischaemic heart disease

Troponins to guide the use of invasive treatment in ACS

Comparing conservative to invasive treatment in patients with acute coronary syndromes (ACS) treated with tiroliban, early invasive treatment showed an 18% reduction in death/myocardial infarction (MI)/repeat ACS within six months. A total of 2220 patients with ACS were enrolled and 1780 completed the six month follow up with cardiac troponin-I (cTnI) available. Patients with a cTnI concentration of > 0.1 ng/ml experienced a significant reduction in the primary end point with the invasive versus conservative strategy (15.3% vs 25.0%; odds ratio [OR] 0.54, 95% confidence interval [CI] 0.40 to 0.73). Patients with cTnI concentrations of < 0.1 ng/ml had no benefit from early invasive management (16.0% vs 12.4%; OR 1.4, 95% CI 0.89 to 2.05, p < 0.001 for interaction). Similar results were observed with cTnT.

The possible association between the use of oral contraceptives and the risk of MI was studied according to the type of progestogen included in third generation oral contraceptives, the dose of oestrogen, and the presence or absence of prothrombotic mutations. A cohort of 248 women aged between 18–49 years were enrolled, with acute MI between 1990 and 1995, and they had a prothrombotic mutation. The risk of myocardial infarction was similar whether or not those with a prothrombotic mutation were enrolled.

Heart failure

Valsartan: not an agent for universal use

Over 5000 patients with heart failure were randomly assigned to receive 160 mg of valsartan or placebo twice daily. Although overall mortality was similar in the two groups, valsartan significantly reduced the combined end point of mortality and morbidity (defined as the incidence of cardiac arrest with resuscitation, hospitalisation for heart failure, or receipt of intravenous treatment) and improved clinical signs and symptoms in patients with heart failure. However, a post hoc observation of an adverse effect on mortality and morbidity in the subgroup receiving valsartan, an ACE inhibitor, and a β blocker at the same time raises concern about the potential safety of this specific combination.

Male cells in a female heart

Cases in which a male patient provided a heart from a female donor provide an unusual opportunity to test whether primitive cells translocate from the recipient to the graft and whether cells with the phenotypic characteristics of those of the recipient ultimately reside in the donor heart. The Y chromosome can be used to detect migrated undifferentiated cells expressing stem cell antigens and to discriminate between primitive cells derived from the recipient and those derived from the donor. Myocytes, coronary arterioles, and capillaries that had a Y chromosome made up 7–10% of those in the donor hearts and were highly proliferative, suggesting migration of primitive cells from the recipient to the grafted heart.

In vivo detection of apoptosis

Cardiomyocyte apoptosis occurs during reperfusion injury, transplant rejection, and heart failure, but detection of apoptosis in the living organism has been limited to histologic analysis of biopsy specimens (TUNEL staining). These two studies describe in vivo techniques for imaging apoptosis in living hearts based on annexin-V binding to externalised phosphatidylserine. Detecting apoptosis in patients would provide valuable information about their clinical condition. It could also be an important window into potential pathogenic mechanisms. In a study of 18 cardiac transplant patients, five patients showed histologic evidence of transplant rejection (indicated by mononuclear cell infiltration or more severe features) and apoptosis (as revealed by immunohistochemical staining for activated caspase-3). These same five patients were found to exhibit myocardial uptake of the 99mTc–annexin-V probe.
General cardiology

PFO and the risk of stroke

A patent foramen ovale (PFO) on its own may have a risk of stroke, but how large is the risk? Of 581 patients (aged 18–55 years) who had had an ischaemic stroke of unknown origin within the preceding three months, after four years the risk of recurrent stroke was 2.3% (95% CI 0.3% to 4.3%) among the patients with PFO alone, 15.2% (95% CI 1.8% to 28.6%) among the patients with both PFO and atrial septal aneurysm, and 4.2% (95% CI 1.8% to 6.6%) among the patients with neither of these cardiac abnormalities. There were no recurrences among the patients with an atrial septal aneurysm alone. All were on aspirin 300 mg/day. The presence of both cardiac abnormalities was a significant predictor of an increased risk of recurrent stroke (hazard ratio for the comparison with the absence of these abnormalities 4.17, 95% CI 1.47 to 11.84), whereas isolated PFO, whether small or large, was not.


Images in Cardiology

Myocardial viability by contrast enhanced MRI in a patient with left bundle branch block showing a severe defect on FDG-PET

A 53 year old male hypertensive patient with no history of previous myocardial infarction presented with exertional dyspnoea and fatigue. The ECG revealed complete left bundle branch block (LBBB), and echocardiography demonstrated moderately reduced left ventricular function (ejection fraction 36%) with anteroseptal and anteroapical located severe hypokinesia and akinisia. Assessment of myocardial viability using \(^{18}\)F-fluoro-deoxyglucose (FDG) positron emission tomography (PET) (left panels showing a midventricular short axis view (top) as well as a horizontal (middle) and a vertical (bottom) long axis view) revealed a severe defect of the septum from base to apex extending to the anterior and inferior wall (white arrowheads) suggesting scar tissue. Contrast enhanced cardiac magnetic resonance imaging (MRI) 15 minutes after gadolinium–DTPA administration using a T1 weighted gradient echo sequence optimised for the detection of scar tissue (which presents as bright myocardial enhancement as opposed to normal black myocardium) revealed complete absence of scar (right panels showing corresponding short axis and long axis views). Atherosclerotic coronary artery disease was excluded at coronary angiography.

The finding of a reduced tracer uptake on FDG-PET images in the septal region of patients with LBBB is not uncommon, leaving uncertainty about the viability status. In this patient with LBBB and severely abnormal FDG-PET scan, absence of scar tissue in the septal region and hence myocardial viability could be confirmed using contrast enhanced MRI. Thus, contrast enhanced MRI may be a valuable adjunct for the assessment of myocardial viability in patients with regional severe wall motion abnormalities and LBBB.

H P Kühl
A P van de Weert
A M Beek
F C Visser
A C van Rossum
ac.vrossum@vumc.nl 01786.f1-A